StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Development — Stock-based compensation expense by Quarter

Development — Stock-based compensation expense ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Development — Stock-based compensation expense: $83.2M in Q2 2026, up 7.9% from a year earlier.

Latest, Q2 2026
83.2
Period ended Jun 30, 2026
Change on a year earlier
+7.9%
77.1 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| Stock-based compensation expense | 83.2 | 77.1 | 8% | 163.7 | 154.9 | 6%”

Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K MD&A (Development Expenses Disaggregation Table).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDevelopment — Stock-based compensation expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202683.2+7.9%Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202680.5+3.5%Form 10-Q (vrtx-20260331.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202577.7+4.9%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2025Sep 30, 202588+7.8%Form 10-Q (vrtx-20250930.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202577.1+12.6%Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202577.8-13.1%Form 10-Q (vrtx-20260331.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 202474.1-17.5%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2024Sep 30, 202481.6+34.7%Form 10-Q (vrtx-20250930.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 202468.5+22.3%Form 10-Q (vrtx-20250630.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 202489.5+59.5%Form 10-Q (vrtx-20250331.htm, filed 2025-05-06) ↗
Q4 2023Dec 31, 202389.8+80.7%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2023Sep 30, 202360.6+6.9%Form 10-Q (vrtx-20240930.htm, filed 2024-11-05) ↗
Q2 2023Jun 30, 202356+12.0%Form 10-Q (vrtx-20240630.htm, filed 2024-08-02) ↗
Q1 2023Mar 31, 202356.1-2.4%Form 10-Q (vrtx-20240331.htm, filed 2024-05-07) ↗
Q4 2022Dec 31, 202249.7-2.5%Form 10-K (vrtx-20241231.htm, filed 2025-02-13) ↗
Q3 2022Sep 30, 202256.7+30.0%Form 10-Q (vrtx-20230930.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Development — Stock-based compensation expense ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-sbc

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.